| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/09/2008 | EP1906932A2 Modified release pharmaceutical compositions on the basis of two polymers and processes thereof |
| 04/09/2008 | EP1906931A1 Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof |
| 04/09/2008 | EP1906930A2 Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof |
| 04/09/2008 | EP1906926A1 Pharmaceutical composition comprising 2 , 3-dihydro-6-nitroimidazo ý2 , 1-b¨oxazole derivatives |
| 04/09/2008 | EP1906921A1 Clear pharmaceutical aqueous microemulsion comprising propofuol and process for preparation |
| 04/09/2008 | EP1906919A2 Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof |
| 04/09/2008 | EP1906917A2 Oral, quickly disintegrating film, which cannot be spit out, for an antiemetic or antimigraine agent |
| 04/09/2008 | EP1906916A2 Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders |
| 04/09/2008 | EP1906912A1 Method for prolonging the life of animals |
| 04/09/2008 | EP1906874A2 Use of heat shock to treat ocular disease |
| 04/09/2008 | EP1906767A1 Lycopene formulations for the treatment of atherosclerotic conditions |
| 04/09/2008 | EP1906766A1 Low-glycemic mixtures |
| 04/09/2008 | EP1906754A2 Novel supplements for poultry and livestock |
| 04/09/2008 | EP1906731A2 Novel hydroxamic acid-containing amino acid derivatives |
| 04/09/2008 | EP1748770B1 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| 04/09/2008 | EP1727793B1 Substituted azetidine compounds as cyclooxygenase-1 - cyclooxygenase-2 inhibitors, and their preparation and use as medicaments |
| 04/09/2008 | EP1720985A4 Polypeptide participating in pyridoxine biosynthesis, a polynucleotide coding the polypeptide and those uses |
| 04/09/2008 | EP1677761B1 Suspension of loteprednol etabonate and tobramycin for topical ophthalmic use |
| 04/09/2008 | EP1594867B1 Phenylacetamides and their use as glucokinase modulators |
| 04/09/2008 | EP1592671B1 N-substituted (benzoimidazole-2-yl) phenyl amines, method for their production, their use as a medicament or diagnostic agent and medicament containing said substances |
| 04/09/2008 | EP1551423B1 Compositions comprising amphotericin B comprising less than 4 % impurities |
| 04/09/2008 | EP1513889B1 Hydrous gel and production process and use of the hydrous gel |
| 04/09/2008 | EP1474171B1 Weight management system for obese animals |
| 04/09/2008 | EP1450853A4 Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions |
| 04/09/2008 | EP1450796B1 Benzothiazole derivatives |
| 04/09/2008 | EP1439837B1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
| 04/09/2008 | EP1429757B1 Crystalline forms of fluvastatin sodium |
| 04/09/2008 | EP1414444B1 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists |
| 04/09/2008 | EP1370247B1 Taste masked pharmaceutical compositions |
| 04/09/2008 | EP1345613B1 Probiotic compounds derived from lactobacillus casei strain ke01 |
| 04/09/2008 | EP1343462B1 Antiperspirant products |
| 04/09/2008 | EP1309565B1 Heterocyclic mutilin esters and their use as antibacterials |
| 04/09/2008 | EP1299348B1 Compounds and compositions for delivering active agents |
| 04/09/2008 | EP1276467B1 Guaifenesin sustained release formulation and tablets |
| 04/09/2008 | EP1228095B1 Modified gp100 and uses thereof |
| 04/09/2008 | EP1173767B1 Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
| 04/09/2008 | EP1140964B1 Connective tissue growth factor (ctgf) fragment |
| 04/09/2008 | EP1135106B1 Sustained release matrix systems for highly soluble drugs |
| 04/09/2008 | EP1124551B1 Delta 9 tetrahydrocannabinol (delta 9 thc) solution metered dose inhalers and methods of use |
| 04/09/2008 | EP1100892B1 Use of prohibitin rna in treatment of cancer |
| 04/09/2008 | EP1082112B1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 04/09/2008 | EP1036175B1 Human brain derived kcnq2 potassium channel |
| 04/09/2008 | EP1027440B1 Inhibitor protein of the wnt signal pathway |
| 04/09/2008 | EP0964864B1 Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| 04/09/2008 | EP0958287B2 Sulfamide-metalloprotease inhibitors |
| 04/09/2008 | CN201044823Y Medicine label for treating deficiency and excess heterogeneous type slow branch acupoint |
| 04/09/2008 | CN101160402A Cancer specific antibody and cell surface proteins |
| 04/09/2008 | CN101160400A Compounds |
| 04/09/2008 | CN101160399A Oligonucleotide compositions and their use for the modulation of immune responses |
| 04/09/2008 | CN101160354A Polymeric pharmaceutical agent for treatment of cancer and process for production of the same |
| 04/09/2008 | CN101160316A Thienopyrimidines useful as aurora kinase inhibitors |
| 04/09/2008 | CN101160315A Cytoskeletal active compounds, composition and use |
| 04/09/2008 | CN101160313A Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents |
| 04/09/2008 | CN101160312A Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents |
| 04/09/2008 | CN101160311A Polymorphic form of 6- (4-chlorophenyl) -2, 2-dimethyl-7-phenyl-2, 3-dihydro-lh-pyrrolizin-5-ylacetic acid |
| 04/09/2008 | CN101160309A Novel imidazo [1, 5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same |
| 04/09/2008 | CN101160308A Methods of treating cancer and related methods |
| 04/09/2008 | CN101160307A Benzoxazole carboxamides for treating cinv and ibs-d |
| 04/09/2008 | CN101160306A 苯并咪唑化合物 Benzimidazole compounds |
| 04/09/2008 | CN101160305A Substituted chroman derivatives, method for the production and the use thereof in the form of antiphlogistics |
| 04/09/2008 | CN101160304A Substituted aryl 1,4-pyrazine derivatives |
| 04/09/2008 | CN101160303A 1-(2H)-isoquinolone derivative |
| 04/09/2008 | CN101160301A Aminoalkyl-amidomethyl-substituted 2- (4-sulphonylamino) -3-hydroxy-3 , 4-dihydro-2h-cromen-6-yl derivatives and their use as potassium channel blockers |
| 04/09/2008 | CN101160297A 2-aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitor (iap) modulators |
| 04/09/2008 | CN101160294A Anti-cancer and anti-microbial oxazolidinones and analogues |
| 04/09/2008 | CN101160293A Azole derivatives in the form of lipase and phospholipase inhibitors |
| 04/09/2008 | CN101160291A 新颖的hsp90抑制剂 Novel hsp90 inhibitor |
| 04/09/2008 | CN101160290A 7-membered ring compound, process for producing the same, and medicinal use thereof |
| 04/09/2008 | CN101160289A Pyridazine derivatives and their use as therapeutic agents |
| 04/09/2008 | CN101160285A Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as vr1 receptor antagonists |
| 04/09/2008 | CN101160284A Organic compounds |
| 04/09/2008 | CN101160282A Acetylene derivatives |
| 04/09/2008 | CN101160281A Crystalline forms of pregabalin |
| 04/09/2008 | CN101160137A Use of CD 25antibody in immunity treatment |
| 04/09/2008 | CN101160132A Polymorphs of 3-o-(3',3'-dimethylsuccinyl)betulinic acid di-n-methyl-d-glucamine |
| 04/09/2008 | CN101160131A Pharmaceutical combination of bcr-abl and raf inhibitors |
| 04/09/2008 | CN101160130A Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome |
| 04/09/2008 | CN101160129A Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients |
| 04/09/2008 | CN101160128A Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient |
| 04/09/2008 | CN101160127A Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy |
| 04/09/2008 | CN101160126A Angiotensin ii receptor antagonists |
| 04/09/2008 | CN101160125A Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 04/09/2008 | CN101160124A Boron-containing small molecules |
| 04/09/2008 | CN101160123A Combinations and modes of administration of therapeutic agents and combination therapy |
| 04/09/2008 | CN101160122A Eutectic blends containing a water soluble vitamin derivative |
| 04/09/2008 | CN101160121A Methods and compositions for treating cancer |
| 04/09/2008 | CN101160120A Sedative effect-providing agent and sedative fragrance composition containing the same |
| 04/09/2008 | CN101160065A Method for treatment and prevention of respiratory insufficiency |
| 04/09/2008 | CN101160053A Stannsoporfin compositions and administration |
| 04/09/2008 | CN101160050A Method and kit for controlling bleeding |
| 04/09/2008 | CN101157924A Neutrophil leukocyte gene alpha |
| 04/09/2008 | CN101157731A Preparation method for low agriculture remanet panax ginseng and American ginseng polysaccharide extractive |
| 04/09/2008 | CN101157726A Deuterohemin short-peptide compound and its application in preparation of anti-cataractogenesis drugs |
| 04/09/2008 | CN101157720A Template fixed peptide analogue as serine protease inhibitor |
| 04/09/2008 | CN101157718A Triterpenoid saponins antineoplastic compound griseaside A in ash sea cucumber and preparation method thereof |
| 04/09/2008 | CN101157717A Preparation method of Ardisia mamillata B and uses thereof |
| 04/09/2008 | CN101157716A Dicarbon drop freedelane triterpenoid and preparation method and uses thereof |
| 04/09/2008 | CN101157715A Ursolic acid chemical modified compound amino alcohol having antitumor activity |
| 04/09/2008 | CN101157714A Hedera helix saponin, preparation method and antineoplastic use thereof |
| 04/09/2008 | CN101157711A Compound having antineoplastic activity and uses thereof |